Effects of p38 MAPK Inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production.

Bao, Weike; Behm, David J; Nerurkar, Sandhya S; Ao, Zhaohui; Bentley, Ross; Mirabile, Rosanna C; Johns, Douglas G; Woods, Tina N; Doe, Christopher P A; Coatney, Robert W; Ohlstein, Jason F; Douglas, Stephen A; Willette, Robert N; Yue, Tian-Li

Bao, Weike; Behm, David J; Nerurkar, Sandhya S; Ao, Zhaohui; Bentley, Ross; Mirabile, Rosanna C; Johns, Douglas G; Woods, Tina N; Doe, Christopher P A; Coatney, Robert W; Ohlstein, Jason F; Douglas, Stephen A; Willette, Robert N; Yue, Tian-Li.

Affiliation

Bao W; Department of Investigative and Cardiac Biology, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA. Weike_2_Bao@gsk.com

J Cardiovasc Pharmacol ; 49(6): 362-8, 2007 Jun.

Article in En | MEDLINE | ID: mdl-17577100

Subject(s)

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Angiotensin II / Superoxides / Ventricular Remodeling / P38 Mitogen-Activated Protein Kinases / Enzyme Inhibitors / Hypertension / Imidazoles Language: En Journal: J Cardiovasc Pharmacol Year: 2007 Document type: Article Affiliation country:

Search on Google

Add to My VHL

XML

PubMed Links